Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
ADC Developments in HER2– Breast Cancer Treatment Shake Up Paradigm
As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.
Pilewskie Highlights Trends for Surgical Management of High-risk Breast Lesions
Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®
Miami Breast Cancer Conference Celebrates 40 Years
March 3rd 2023The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.
Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies
February 28th 2023With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.
Wang Details Caveats to Standards of Care for Treating Patients With MCL
February 28th 2023When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.
Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric Cancer
February 27th 2023Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.
Dr. Wang on Contraindications to Hypomethylating Therapy in Older Patients With AML
February 24th 2023Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population
Dr. Cortes on Better Understanding Areas of Interest in ALL
February 24th 2023Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.
Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate Cancer
February 23rd 2023Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.
TTFields With Chemotherapy Under Investigation in Locally Advanced Pancreatic Cancer
Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.
PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer
Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.
Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPC
February 21st 2023Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.
New Technology Advances Prostate Cancer Care But Questions Linger
February 21st 2023Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.
Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer Care
February 21st 2023Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .
Nivolumab Plus Salvage Immunotherapy Leads to High TFS Rates in Advanced RCC
February 21st 2023Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
